Literature DB >> 11374025

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.

G Chinetti1, J C Fruchart, B Staels.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors which function as regulators of lipid and lipoprotein metabolism and glucose homeostasis and influence cellular proliferation, differentiation and apoptosis. PPAR alpha is highly expressed in liver, muscle, kidney and heart, where it stimulates the beta-oxidative degradation of fatty acids. PPAR gamma is predominantly expressed in intestine and adipose tissue, where it triggers adipocyte differentiation and promotes lipid storage. Recently, the expression of PPAR alpha and PPAR gamma was also reported in cells of the vascular wall, such as monocyte/macrophages, endothelial and smooth muscle cells. The hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPAR alpha and PPAR gamma, respectively. Furthermore, fatty acid-derivatives and eicosanoids are natural PPAR ligands: PPAR alpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPAR gamma ligand, as well as some components of oxidized LDL, such as 9- and 13-HODE. These observations suggested a potential role for PPARs not only in metabolic but also in inflammation control and, by consequence, in related diseases such as atherosclerosis. More recently, PPAR activators were shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNF alpha and metalloproteases) by negatively interfering with the NF-kappa B, STAT and AP-1 signalling pathways in cells of the vascular wall. Furthermore, PPARs may also control lipid metabolism in the cells of the atherosclerotic plaque. In addition, different clinical trials (such as the LOCAT, BECAIT and VA-HIT) as well as animal studies indicate that PPAR activators may have anti-atherogenic properties by reducing the progression of atherosclerotic lesions. In this review, we summarize the evidence indicating that PPAR alpha and PPAR gamma directly modulate vessel wall functions, and its consequences in the control of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374025     DOI: 10.1007/s003920170034

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  17 in total

Review 1.  Transcriptional control of macrophage polarisation in type 2 diabetes.

Authors:  Karima Drareni; Jean-François Gautier; Nicolas Venteclef; Fawaz Alzaid
Journal:  Semin Immunopathol       Date:  2019-05-02       Impact factor: 9.623

2.  High salt diet modulates vascular response in A2AAR (+/+) and A 2AAR (-/-) mice: role of sEH, PPARγ, and K ATP channels.

Authors:  Isha Pradhan; Catherine Ledent; S Jamal Mustafa; Christophe Morisseau; Mohammed A Nayeem
Journal:  Mol Cell Biochem       Date:  2015-03-05       Impact factor: 3.396

3.  Suppression of the ELO-2 FA elongation activity results in alterations of the fatty acid composition and multiple physiological defects, including abnormal ultradian rhythms, in Caenorhabditis elegans.

Authors:  Marina Kniazeva; Matt Sieber; Scott McCauley; Kang Zhang; Jennifer L Watts; Min Han
Journal:  Genetics       Date:  2003-01       Impact factor: 4.562

4.  Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-α-induced injury.

Authors:  Gang Zhao; Jianing Wang; Xizhen Xu; Yanyan Jing; Ling Tu; Xuguang Li; Chen Chen; Katherine Cianflone; Peihua Wang; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  J Lipid Res       Date:  2012-01-05       Impact factor: 5.922

5.  Peroxisome proliferator-activated receptor gamma/signal transducers and activators of transcription 5A pathway plays a key factor in adipogenesis of human bone marrow-derived stromal cells and 3T3-L1 preadipocytes.

Authors:  Ho Sun Jung; Yoo Jeong Lee; Yun Hee Kim; Seungil Paik; Jae Woo Kim; Jin Woo Lee
Journal:  Stem Cells Dev       Date:  2011-06-15       Impact factor: 3.272

6.  Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation.

Authors:  Peter Zahradka; Natalia Yurkova; Brenda Litchie; Michael C Moon; Dario F Del Rizzo; Carla G Taylor
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

7.  Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation.

Authors:  Hnin H Aung; Michael W Lame; Kishorchandra Gohil; Chung-Il An; Dennis W Wilson; John C Rutledge
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-18       Impact factor: 8.311

8.  The effects of estrogen and testosterone on gene expression in the rat mesenteric arteries.

Authors:  Kathleen M Eyster; Connie J Mark; Richard Gayle; Douglas S Martin
Journal:  Vascul Pharmacol       Date:  2007-07-03       Impact factor: 5.773

9.  Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia.

Authors:  K Jagadeesha Dammanahalli; Stephanie Stevens; Robert Terkeltaub
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

10.  Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion.

Authors:  Jinru Wei; Quan Tang; Lijuan Liu; Jianbin Bin
Journal:  Exp Ther Med       Date:  2013-01-10       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.